Certara Inc (CERT)

Currency in USD
5.22
+0.05(+0.87%)
Real-time Data·
CERT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.065.29
52 wk Range
4.4513.88
Key Statistics
Prev. Close
5.17
Open
5.14
Day's Range
5.06-5.29
52 wk Range
4.45-13.88
Volume
2.37M
Average Volume (3m)
3.89M
1-Year Change
-54.5296%
Book Value / Share
6.39
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CERT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.62
Upside
+45.94%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Certara Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Analyst Ratings

5 Buy
7 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.62
(+45.94% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Morgan Stanley
Hold10.00+91.94%11.00Maintain12/05/2026
BMO Capital
Hold6.00+15.16%7.00Maintain12/05/2026
Stephens
Buy9.00+72.74%10.00Maintain12/05/2026
Baird
Hold6.00+15.16%7.00Maintain12/05/2026
Barclays
Hold6.50+24.76%8.00Maintain12/05/2026

Certara Inc SWOT Analysis


Biosim Breakthrough
Certara leads in biosimulation software, with Q2 revenue of $104.6M, up 12% YoY. Strong financials and market position drive growth in drug development tech.
Animal Testing Pivot
Explore Certara's push into animal testing alternatives, targeting a multi-billion dollar market. This aligns with FDA's move to phase out animal testing.
Valuation Insights
Analysts set an average price target of $14, reflecting Certara's premium valuation. The company trades at 15x estimated 2025 EBITDA, above some peers.
Future-Proofing Strategy
Learn about CertaraIQ, launching Q4 2025, and how it could boost the company's competitive edge in the evolving biosimulation landscape.
Read full SWOT analysis

Certara Inc Earnings Call Summary for Q1/2026

  • Q1 2026 EPS of $0.09 missed forecast of $0.11 by 18%; revenue of $106.9M slightly beat expectations, up 1% YoY
  • Stock plunged 19.33% to $5.09 post-announcement; down 59% over past year, trading near 52-week low of $4.78
  • Software segment grew 7% YoY to $49.7M driven by Simcyp and Phoenix; services revenue declined 4% YoY to $57.2M
  • Company forecasts EPS improvement to $0.11 in Q2 2026 and $0.12 in Q3 2026; analyst price targets range $6-$10
  • CEO cited profitability challenges; focusing on AI-integrated platform development and cost rationalization to enhance margins
Last Updated: 14/05/2026, 13:32
Read Full Transcript

Earnings

Latest Release
11/05/2026
EPS / Forecast
0.09 / 0.11
Revenue / Forecast
106.9M / 106.1M
EPS Revisions
Last 90 days

Compare CERT to Peers and Sector

Metrics to compare
CERT
Peers
Sector
Relationship
P/E Ratio
−53.5x−0.4x−0.5x
PEG Ratio
0.13−0.020.00
Price/Book
0.8x1.5x2.6x
Price / LTM Sales
1.9x1.4x3.1x
Upside (Analyst Target)
54.7%37.8%53.0%
Fair Value Upside
Unlock37.9%6.3%Unlock

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Employees
1546

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
68.37M43.95%353.49M
Other Institutional Investors
123.03M56.05%636.06M
Public Companies & Retail Investors
0.000.00%0.00
Total
191.4M100.00%989.56M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Arsenal Capital Management LP23.36%36,345,835187,908
BlackRock, Inc.8.95%13,926,86372,002

People Also Watch

4.97
OPRX
+0.61%
8.97
BRBR
-0.94%
100.80
RPM
+1.60%
115.92
ATR
+0.35%
17.89
UPBD
+1.07%

FAQ

What Is the Certara (NASDAQ: CERT) Share Price Today?

The Certara stock price today is 5.22 USD.

What Stock Exchange Does Certara (CERT) Trade On?

Certara is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Certara?

The stock symbol (also called a 'ticker') for Certara is "CERT."

What Is the Current Certara Market Capitalisation?

As of today, Certara (NASDAQ: CERT) market cap is 812.05M USD.

What Is Certara's (CERT) Earnings Per Share (TTM)?

The Certara EPS is currently -0.10 (Trailing Twelve Months).

When Is the Next Certara Earnings Date?

Certara's next earnings report will be released on 11/08/2026.

Is CERT a Buy or Sell From a Technical Analyst Perspective?

Based on today's Certara moving averages and other technical indicators, the daily buy/sell signal for CERT stock is Strong Sell.

How Many Times Has Certara Stock Split?

Certara has split 0 times. (See the CERT stock split history page for full effective split date and price information.)

How Many Employees Does Certara Have?

Certara has 1546 employees, based on their latest Companies House report.

What is the current trading status of Certara (NASDAQ: CERT)?

As of 22/05/2026, Certara (CERT) is trading at a share price of 5.22 USD, with a previous close of 5.17 USD. The stock has fluctuated within a day range of 5.06 USD to 5.29 USD, while its 52-week range spans from 4.45 USD to 13.88 USD.

What Is Certara (CERT) Price Target According to Analysts?

The average 12-month price target for Certara is 7.62 USD, with a high estimate of 10 USD and a low estimate of 6 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +45.94% Upside potential.

What Is the CERT Premarket Price?

CERT's last pre-market stock price is 5.11 USD. The pre-market share volume is 1,470.00, and the stock has decreased by -0.06, or -1.16%.

What Is the CERT After Hours Price?

CERT's last after hours stock price is 5.16 USD, the stock has decreased by -0.01, or -0.19%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.